Denali Therapeutics and Corcept Therapeutics Win FDA Approvals
Denali and Corcept secure FDA approvals while Allogene advances off-the-shelf CAR-T, per STAT+ newsletter.
Denali Therapeutics and Corcept Therapeutics have won FDA approvals, according to STAT News' Readout Newsletter published March 26, 2026. The newsletter also notes that Sarepta Therapeutics is eyeing a rebound and Allogene is progressing with an off-the-shelf CAR-T therapy. This is industry regulatory news rather than a peer-reviewed research study; no details on study design (e.g., RCT vs observational), sample size, or conflicts of interest are provided in the source. Source URL: https://www.statnews.com/2026/03/26/denali-corcept-fda-allogene-car-t-readout-newsletter/?utm_campaign=rss
VITALIS: This means ordinary people with tough brain or hormone disorders could soon get easier access to new treatments that actually work better than what's out there now. It points to a future where life-changing medicines arrive faster and feel less out of reach for regular families.
Sources (1)
- [1]STAT+: Denali Therapeutics, Corcept Therapeutics win FDA approvals(https://www.statnews.com/2026/03/26/denali-corcept-fda-allogene-car-t-readout-newsletter/?utm_campaign=rss)